Ogunbiyi O A, Scholefield J H, Smith J H, Polacarz S V, Rogers K, Sharp F
University Department of Surgery, Northern General Hospital, Sheffield.
J Clin Pathol. 1993 Jun;46(6):507-12. doi: 10.1136/jcp.46.6.507.
To determine the pattern of expression of the p53 tumour suppressor gene product in anal squamous neoplasia, and to determine if this could be used as a marker of disease progression. The association between p53 expression and human papillomavirus (HPV) 16 DNA status of the anal lesions was also investigated.
The presence and localisation of the p53 protein in formalin fixed, paraffin wax embedded specimens of anal squamous epithelium (normal and neoplastic) was examined using immunohistochemical staining with a panel of two monoclonal antibodies (DO-1, DO-7) and one polyclonal antibody (CM-1). Thirty nine normal anal epithelia, 14 anal intraepithelial neoplasia (AIN) grade 1, seven AIN 2, and 20 AIN 3 specimens were obtained from patients without demonstrable invasive disease; twelve AIN 3 specimens adjacent to invasive disease and 34 anal squamous cancers were also examined. Genomic DNA from all 126 specimens was extracted and analysed for HPV 16 DNA using the polymerase chain reaction (PCR).
Nuclear p53 was strongly expressed in 67% (23/34) of invasive anal squamous tumours, 75% (9/12) of AIN 3 specimens adjacent to invasive disease, and in 60% (12/20) of AIN 3 specimens obtained from patients without demonstrable invasive disease. Two of the patients in the latter group with positively staining specimens subsequently developed invasive tumours which had staining characteristics similar to those of the AIN 3 specimens. p53 protein was expressed in very low concentrations in low grade AIN and not at all in normal anal squamous epithelium. In those specimens which stained positively for p53, HPV 16 DNA sequences were detected in 69.5% (16/23) of invasive disease, 77.7% (7/9) of AIN 3 adjacent to invasive disease, 75% (9/12) of AIN 3 obtained from patients without demonstrable invasive disease, 33.3% (2/6) of AIN 2, and in 40% (2/5) of AIN 1. There was no significant correlation between p53 immunostaining and HPV 16 DNA status (p < 0.05).
Aberrant expression of the p53 gene product is probably involved in the pathogenesis of anal squamous neoplasia. Long term follow up studies of all patients with AIN are required to determine if this could be used as a marker of likely disease progression from high grade AIN to invasive disease. There does not seem to be an association between the presence or absence of HPV 16 DNA sequences and mutant p53 proteins in anal squamous neoplasia.
确定p53肿瘤抑制基因产物在肛管鳞状上皮肿瘤中的表达模式,并确定其是否可作为疾病进展的标志物。同时研究p53表达与肛管病变中人乳头瘤病毒(HPV)16 DNA状态之间的关联。
使用一组两种单克隆抗体(DO-1、DO-7)和一种多克隆抗体(CM-1)进行免疫组织化学染色,检查福尔马林固定、石蜡包埋的肛管鳞状上皮(正常和肿瘤性)标本中p53蛋白的存在和定位。从无明显浸润性疾病的患者中获取39例正常肛管上皮、14例1级肛管上皮内瘤变(AIN)、7例2级AIN和20例3级AIN标本;还检查了12例与浸润性疾病相邻的3级AIN标本和34例肛管鳞状癌标本。提取所有126例标本的基因组DNA,使用聚合酶链反应(PCR)分析HPV 16 DNA。
在34例浸润性肛管鳞状肿瘤中,67%(23/34)有强烈的核p53表达;在12例与浸润性疾病相邻的3级AIN标本中,75%(9/12)有表达;在从无明显浸润性疾病的患者中获取的20例3级AIN标本中,60%(12/20)有表达。后一组中两名p53染色阳性标本的患者随后发生了浸润性肿瘤,其染色特征与3级AIN标本相似。p53蛋白在低级别AIN中以非常低的浓度表达,在正常肛管鳞状上皮中完全不表达。在p53染色阳性的标本中,69.5%(16/23)的浸润性疾病、77.7%(7/9)与浸润性疾病相邻的3级AIN、75%(9/12)从无明显浸润性疾病的患者中获取的3级AIN、33.3%(2/6)的2级AIN以及40%(2/5)的1级AIN中检测到HPV 16 DNA序列。p53免疫染色与HPV 16 DNA状态之间无显著相关性(p<0.05)。
p53基因产物的异常表达可能参与肛管鳞状上皮肿瘤的发病机制。需要对所有AIN患者进行长期随访研究,以确定其是否可作为从高级别AIN进展为浸润性疾病的可能标志物。在肛管鳞状上皮肿瘤中,HPV 16 DNA序列的有无与突变p53蛋白之间似乎没有关联。